Forest Services
Introduction: India's Shield Against Patented Drug Tariffs
India operates a robust patent regime under the Patents Act, 1970 (amended 2005) combined with strategic tariff policies and international flexibilities under the TRIPS Agreement of the WTO. These frameworks collectively shield India from exorbitant patented drug tariffs, ensuring affordable access to essential medicines. Key legal provisions such as Section 3(d) prevent patent evergreening, while Sections 48 and 84 enable compulsory licensing to counter monopolistic pricing. The Drug Price Control Order (DPCO), 2013 further regulates prices of essential medicines under the Essential Commodities Act, 1955. This multi-layered approach has kept patented drugs’ share below 10% of the Indian market by value, maintaining affordability despite global price inflation.
UPSC Relevance
- GS Paper 2: Governance – Intellectual Property Rights, Health Policies, WTO and TRIPS Agreement
- GS Paper 3: Economic Development – Pharmaceutical industry, Price regulation, Innovation and Public Health
- Essay: Balancing Patent Rights and Access to Medicines in India
Legal Framework Governing Patented Drugs and Tariffs
The Patents Act, 1970, amended in 2005 to comply with TRIPS, includes critical sections that regulate pharmaceutical patents:
- Section 3(d): Prevents patent evergreening by disallowing patents for minor modifications that do not enhance therapeutic efficacy, upheld by the Supreme Court in Novartis AG v. Union of India (2013).
- Section 48: Governs the grant of compulsory licenses to third parties under specific conditions.
- Section 84: Allows compulsory licensing if patented drugs are not available at affordable prices or in adequate quantity, exemplified by the 2012 compulsory license for Bayer’s Nexavar, which reduced prices by 97%.
The Drug Price Control Order (DPCO), 2013, enforced by the National Pharmaceutical Pricing Authority (NPPA), caps prices of essential medicines, including some patented drugs. The WTO’s TRIPS Agreement provides flexibilities that India has leveraged, such as compulsory licensing and parallel importation, to protect public health.
Economic Landscape of India’s Pharmaceutical Sector
India’s pharmaceutical market was valued at USD 42 billion in 2023 (IBEF), with generic drugs constituting approximately 70% of the domestic market by volume (Pharma India 2023 report). Patented drugs represent less than 10% of the market by value (Economic Survey 2024). The government’s budget allocation for pharmaceuticals and health in 2024 stands at INR 89,155 crore, reflecting policy emphasis on affordable healthcare.
- Compulsory licensing, notably for Bayer’s Nexavar in 2012, led to a 97% price reduction, demonstrating the economic impact of patent law flexibilities.
- India’s pharmaceutical exports reached USD 25 billion in FY 2023 (Pharmexcil), underlining the global competitiveness of its generic drug industry.
- Despite the dominance of generics, India imports certain patented drugs, but tariff and price controls limit excessive cost escalation.
Institutional Roles in Patent and Drug Price Regulation
Several institutions coordinate India’s pharmaceutical patent and tariff policies:
- Controller General of Patents, Designs and Trade Marks (CGPDTM): Examines and grants patents, ensuring compliance with Section 3(d) and other provisions.
- National Pharmaceutical Pricing Authority (NPPA): Enforces DPCO, regulates prices of essential and patented drugs.
- Department of Pharmaceuticals (DoP): Formulates policy on pharmaceuticals, including patent and pricing strategies.
- Pharmaceuticals Export Promotion Council of India (Pharmexcil): Promotes exports, balancing domestic affordability with global competitiveness.
- World Trade Organization (WTO): Oversees TRIPS compliance and facilitates flexibilities for developing countries.
Comparative Analysis: India vs. United States on Patented Drug Pricing
| Aspect | India | United States |
|---|---|---|
| Patent Law Provisions | Strict anti-evergreening (Section 3(d)), compulsory licensing (Section 84) | Weaker restrictions on evergreening, no compulsory licensing |
| Price Control Mechanism | DPCO caps prices on essential and some patented drugs | No direct government price control on patented drugs |
| Patented Drug Price Level | Up to 90% lower than US prices (IQVIA Institute 2023) | Among highest globally due to monopoly pricing |
| Market Share of Patented Drugs | Less than 10% by value | Majority of pharmaceutical market value |
| Use of TRIPS Flexibilities | Active use of compulsory licensing and patent law flexibilities | Minimal use of TRIPS flexibilities |
Critical Challenges and Policy Gaps
India’s patent and tariff regime effectively shields against high patented drug tariffs but faces challenges:
- Limited local R&D investment restricts innovation in novel patented drugs, slowing availability of cutting-edge therapies.
- Delays in patent examination by CGPDTM can postpone market entry of new patented drugs.
- Balancing incentives for pharmaceutical innovation with access remains contentious, as overemphasis on compulsory licensing may deter investment.
- Tariff policies must continuously adapt to global trade dynamics and patent disputes to maintain affordability.
Significance and Way Forward
- India’s patent law, combined with DPCO and TRIPS flexibilities, provides a replicable model for affordable drug access in developing countries.
- Enhancing CGPDTM capacity to expedite patent examination can improve timely access to innovative medicines.
- Increasing public and private R&D funding will help balance innovation incentives with access goals.
- Continued vigilance against evergreening and strategic use of compulsory licensing will protect public health without undermining patent rights.
- Strengthening coordination among DoP, NPPA, and Pharmexcil can optimize domestic affordability and export growth.
- It is allowed under Section 84 if the patented drug is not available at a reasonable price.
- Compulsory licensing can be issued only after three years from the date of patent grant.
- It can be granted without the patent holder’s consent in case of national emergency.
Which of the above statements is/are correct?
- It allows patenting of new forms of known substances if they show enhanced efficacy.
- It prevents evergreening by disallowing patents for minor modifications without therapeutic benefit.
- It was upheld by the Supreme Court in the Novartis AG v. Union of India case.
Which of the above statements is/are correct?
What is the significance of Section 3(d) in India’s Patents Act?
Section 3(d) prevents patent evergreening by disallowing patents for new forms of known substances unless they show enhanced therapeutic efficacy. This provision was upheld by the Supreme Court in Novartis AG v. Union of India (2013), ensuring that minor modifications do not extend patent monopolies unjustifiably.
How does compulsory licensing under Section 84 work in India?
Section 84 allows the government to grant compulsory licenses if patented drugs are not available in adequate quantity or at reasonable prices, or in cases of national emergency. The first compulsory license was issued in 2012 for Bayer’s Nexavar, reducing its price by 97%.
What role does the Drug Price Control Order (DPCO), 2013 play in drug pricing?
DPCO regulates prices of essential medicines, including some patented drugs, under the Essential Commodities Act, 1955. The National Pharmaceutical Pricing Authority (NPPA) enforces these controls to keep drug prices affordable.
How does India’s pharmaceutical market composition affect patented drug tariffs?
Generics constitute 70% of India’s pharmaceutical market by volume, while patented drugs account for less than 10% by value. This dominance of generics reduces dependency on expensive patented drugs, limiting the impact of high tariffs.
What challenges does India face despite its strong patent regime?
India faces challenges such as limited local R&D investment, delays in patent examination, and balancing innovation incentives with access. These factors can delay introduction of novel patented drugs and complicate policy decisions focused solely on tariffs and compulsory licensing.
About LearnPro Editorial Standards
LearnPro editorial content is researched and reviewed by subject matter experts with backgrounds in civil services preparation. Our articles draw from official government sources, NCERT textbooks, standard reference materials, and reputed publications including The Hindu, Indian Express, and PIB.
Content is regularly updated to reflect the latest syllabus changes, exam patterns, and current developments. For corrections or feedback, contact us at admin@learnpro.in.